Scientists once hoped that blocking β-secretase would slow or prevent Alzheimer’s disease. Then came the rude awakening. The inhibitors caused the very thing they were supposed to prevent—cognitive ...

Merck, known as MSD outside the United States and Canada, and GE Healthcare have announced a clinical study collaboration, license and supply agreement for use of [18F] Flutemetamol, an ...

LONDON (Reuters) - AstraZeneca (AZN.L) has signed a partnership deal with U.S. rival Eli Lilly (LLY.N) that could earn the British company up to $500 million (308.86 million pounds) if a promising – ...

ASTRAZENECA AND LILLY ANNOUNCE ALLIANCE TO DEVELOP AND COMMERCIALISE BACE INHIBITOR AZD3293 FOR ALZHEIMER'S DISEASE AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to ...

Merck & Co has stopped a trial of its Alzheimer’s drug verubecestat, an independent panel concluding there was “virtually no chance” it would help patients with mild to moderate disease. Merck & Co ...

LONDON, Sept 16 (Reuters) - AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising - but risky - experimental ...

Scientists in industry and academia were shocked and saddened to hear of the sudden passing of Bruce Albala. Albala died in Greece on October 16 while celebrating his 40th wedding anniversary with his ...

Eli Lilly and Company has stopped phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the progression of ...

Sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. After a review of clinical data from the Generation Program studies, Novartis, Amgen and Banner ...

LONDON, May 7 (Reuters) - AstraZeneca AZN.L , fighting a $106 billion bid approach from Pfizer PFE.N , is talking to other companies as it seeks a partnering deal for its experimental Alzheimer's drug ...

LONDON (Reuters) - AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million (308.86 million pounds) if a promising – but risky – ...